Academia.eduAcademia.edu

Penile metastasis of prostatic adenocarcinoma. Case report

2011, PubMed

Objective: Penile metastases are late manifestations of a primary tumor, and they are a sign of poor prognosis. We report a case of a rare presentation: penile metastases from prostate cancer. Methods: 77 year-old male presented hematuria and acute urinary retention; on physical examination multiple hard lesions were detected. The patient underwent a Doppler ultrasound, subsequent penile and prostate biopsy, and staging study. Currently he is being treated with complete androgen blockade. Results: A histological study of the penile biopsy showed penile metastasis from prostate adenocarcinoma. The histological study of prostate biopsy confirmed Gleason 8 (4+4) adenocarcinoma. Conclusions: Despite of the different therapeutic alternatives for treatment of symptomatic penile metastases, it would be with palliative target; due to the median survival of these patients is less than a year.

World Journal of Surgical Oncology BioMed Central Open Access Case report Penile metastasis of prostatic adenocarcinoma: Report of two cases and review of literature Joe Philip*1 and Joseph Mathew2 Address: 1Department of Urology, Royal Cornwall Hospital (Treliske), Truro, Cornwall, TR1 3LJ, United Kingdom and 2Department of Histopathology, Royal Cornwall Hospital (Treliske), Truro, Cornwall, TR1 3LJ, United Kingdom Email: Joe Philip* - [email protected]; Joseph Mathew - [email protected] * Corresponding author Published: 14 September 2003 World Journal of Surgical Oncology 2003, 1:16 Received: 27 July 2003 Accepted: 14 September 2003 This article is available from: http://www.wjso.com/content/1/1/16 © 2003 Philip and Mathew; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. Prostateadenocarcinomapenile metastasisquality of life Abstract Background: Carcinoma of the prostate metastasising to the penis is rare. These patients have a poor prognosis receiving various treatment modalities. Case presentation: Two such patients are discussed here having received differing therapeutic regimes, pointing out the necessity for standardised palliative treatment rather than radical therapy. Conclusion: Management of patients with penile metastases from carcinoma of the prostate should emphasise improving quality of life with palliative treatment rather than radical therapy Introduction Metastasis to the penis is rare, despite rich vascularisation and complex circulation. These most commonly arise from the prostate and the bladder [1,2]. It is a debilitating near terminal condition at presentation with a dismal prognosis. Conservative management is generally advocated with emphasis on improvement of quality of life. Therapeutic modalities used include radical penile amputation and radical radiotherapy. We discuss two patients who underwent differing treatment; the presenting features and symptomatology of all other cases reported in the literature have been reviewed. Case 1 A 92-year-old man presented as an emergency with bleeding per urethra. Multiple painful 2 × 2 cm hard nodules were seen around the coronal sulcus (PSA = 299 ng/ml). He had had a primary well-differentiated adenocarcinoma of the prostate diagnosed 11 years previously. His treatment included bilateral orchidectomy and cyproterone acetate. A clinical diagnosis of penile metastases was made. In view of the multiple small nodules, urethral ulceration, local obstructive symptoms and severe penile pain; surgery was considered instead of external beam radiotherapy. A subtotal penectomy with perineal urethrostomy was performed. The surgery was straightforward with remarkably little blood loss, probably a result of genital atrophy secondary to long-term androgen withdrawal. Histology confirmed the presence of metastatic moderately well differentiated prostatic adenocarcinoma (Figure 1) extending through the length of the penis and into the glans and spreading to the surface of the skin at the corona with vascular and lymphatic permeation. There was also urethral ulceration. Immunohistochemistry for PSA confirmed histological diagnosis. Pain relief was rapid with a significant improvement of post-operative quality of life. Page 1 of 3 (page number not for citation purposes) World Journal of Surgical Oncology 2003, 1 http://www.wjso.com/content/1/1/16 Figure 1the Histology invading confirms corporathe cavernosa presence(CC) of invasive (15×, H/E) adenocarcinoma Histology confirms the presence of invasive adenocarcinoma invading the corpora cavernosa (CC) (15×, H/E). Figure Immunohistochemistry ity for prostatic 2 specific shows antigenmembrane (120×) and luminal positivImmunohistochemistry shows membrane and luminal positivity for prostatic specific antigen (120×). Case 2 having additional cystoscopies. 33 patients underwent surgery such as penile amputation, cystostomy and bilateral orchidectomy. Fifteen patients each received radiation and hormonal treatment. These patients had a poor prognosis with survival documented at between 10 days and 84 months, with an average of 6 months, from presentation. An 85-year-old man was admitted as an emergency with symptoms of painful urinary outflow obstruction. Transurethral prostatic resection four years previously had showed a Gleason's Grade 9 prostatic adenocarcinoma; bilateral orchidectomy was performed, followed by cyproterone acetate. Clinical examination revealed palpable nodular 3 × 1 cm lesions at the penile and bulbar urethra (PSA = 41.7 ng/ml). Biopsy of these nodules showed several malignant glandular structures infiltrating the corpus cavernosa of the penis suggestive of a poorly differentiated adenocarcinoma, confirmed immunohistologically (Figure 2) as of prostatic origin. Suprapubic catheterisation was followed by immediate pain relief and marked improvement in quality of life. He is currently receiving palliative care. Review of literature Ninety-eight cases of penile metastases from prostate cancer were identified in the literature [3–10]. Patients were between 42 to 93 years (average 70 years). Urinary symptoms were noted in 28 patients, varying in severity from urethral bleeding to complete urinary retention. Priapism was reported in half the patients, ten of whom also had urinary retention. In 16 patients, the presenting symptom was penile pain; seven of whom had palpable penile nodules. Of 75 patients, metastases was restricted to the corpora cavernosa in 32 patients, glans penis in 12, urethra in four, skin/prepuce in four and corpus spongiosum in three and 20 having multiple involved areas. Biopsy was the mainstay of diagnosis in all the patients with three Discussion Metastatic spread from the prostate to the penis occurs by several routes [7,10], retrograde venous or lymphatic spread, and direct extension are the commonest mechanisms. The most reliable diagnostic modality remains the needle core biopsy; this allows for histological and immunological confirmation of metastatic spread, and evaluation of extent of invasion [5]. Treatment options depend on the general condition of the patient, site and extent of the primary tumour, presence of metastases, and symptomatology. The treatment options available include local excision of the tumour, radiation therapy, bilateral orchidectomy, additional hormonal and/or chemotherapy and, partial or total amputation of the penis. In patients who present with urinary tract outflow obstruction, procedures such as cystostomy or suprapubic catheterisation are of palliative value [7]. Amputation of the penis with urethrostomy formation is to be considered in patients with ulceration, irritating secretion and intractable penile pain for symptom control. In one of our cases treatment followed palliative lines but in the other, subtotal penectomy for severe intractable penile pain, resulted in immediate pain relief and marked Page 2 of 3 (page number not for citation purposes) World Journal of Surgical Oncology 2003, 1 http://www.wjso.com/content/1/1/16 improvement in quality of life. Emphasis should be on palliative treatment and improving quality of life in view of the poor prognosis and a 6-month mortality of 80%. Surgery could be a therapeutic option, but only in patients attended with severe intractable pain. Acknowledgements We would like to acknowledge the invaluable advice and assistance of Mr David Vinnell and Mrs Tracey Smyth in preparing the microphotographs in this manuscript References 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. Tu SM, Reyes A, Maa A, Bhowmick D, Pisters LL, Pettaway CA, Lin SH, Troncoso P and Logothetis CJ: Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 2002, 94:2610-2617. Haddad FS and Manne RK: Prostatic tumors with penile secondaries: review of the literature with a case report. Urol Int 1986, 41:465-470. Senkul T, Karademir K, Silit E, Iseri C, Erden D and Baloglu H: Penile metastasis of prostate adenocarcinoma. Int J Urol 2002, 9:597-598. Geetha G, Nagarajan V, Tulasi NR and Nagarajan M: Carcinoma prostate with penile metastases. A case report. Indian J Cancer 2002, 39:73-74. Chan PT, Begin LR, Arnold D, Jacobson SA, Corcos J and Brock GB: Priapism secondary to penile metastasis: A report of two cases and a review of literature. J Surg Oncol 1998, 68:51-59. Buchholz NP, Moch H, Feichter GE, Schmid HP and Mihatsch MJ: Clinical and pathological features of highly malignant prostatic carcinomas with metastases to the penis. Urol Int 1994, 53:135-138. Osther PJ and Lontoft E: Metastasis to the penis: case reports and review of the literature. Int Urol Nephrol 1991, 23:161-167. Savion M, Livne PM, Mor C and Servadio C: Mixed carcinoma of the prostate with penile metastases and priapism. Eur Urol 1987, 13:351-352. Patel NP and Ward JN: Cancer of the prostate metastatic to prepuce and glans. Urology 1978, 11:269-270. Hamm FC and Weinberg SR: Secondary malignant infiltration of the penis: report of four cases, two with surgical treatment for palliation. J Urol 1955, 73:349-354. Publish with Bio Med Central and every scientist can read your work free of charge "BioMed Central will be the most significant development for disseminating the results of biomedical researc h in our lifetime." Sir Paul Nurse, Cancer Research UK Your research papers will be: available free of charge to the entire biomedical community peer reviewed and published immediately upon acceptance cited in PubMed and archived on PubMed Central yours — you keep the copyright BioMedcentral Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp Page 3 of 3 (page number not for citation purposes)